Bladder clear cell adenocarcinoma

Summary

Bladder clear cell adenocarcinoma (MONDO:0003386) is a disease and 1 clinical trial. Top therapeutic interventions include cabozantinib and ipilimumab. A subtype of bladder adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bladder clear cell adenocarcinoma
Mondo ID	MONDO:0003386
DOID	DOID:5306
NCIT	C6179
UMLS	C1332557
MedGen	272370
Anatomy (UBERON)	UBERON:0001255
Is cancer (heuristic)	no

Also known as: bladder clear cell adenocarcinoma · urinary bladder clear cell adenocarcinoma

Disease family

This is a subtype of bladder adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › bladder adenocarcinoma › bladder clear cell adenocarcinoma

Related subtypes (6): bladder colloid adenocarcinoma, bladder signet ring cell adenocarcinoma, bladder colonic type adenocarcinoma, bladder urachal adenocarcinoma, bladder mixed adenocarcinoma, bladder hepatoid adenocarcinoma

Subtypes (3): bladder diffuse clear cell adenocarcinoma, bladder tubulo-cystic clear cell adenocarcinoma, bladder papillary clear cell adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03866382	PHASE2	RECRUITING	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	3
IPILIMUMAB	4	1